This text is a result of machine translation.
A new breakthrough in the first-line treatment of advanced esophageal cancer: PD-1 monoclonal antibody baizean ® Global phase 3 clinical trials reached the primary end point
Baiji China: the tentative list is a normal step and will not affect the listing of the company on NASDAQ
Ministry of agriculture and rural areas: implement the ten-year fishing ban on the Yangtze River in 2022 and promote the conservation of aquatic biological resources
Hillhouse Q4 position: increased holdings of ideal automobile and Xiaopeng automobile sea, and ideal automobile rushed into the top ten
Hong Kong Pharmaceutical stocks generally rose, with Cinda biology up nearly 6%
54% off! Pamipali, the first PARP inhibitor approved for the treatment of platinum sensitive and platinum resistant recurrent ovarian cancer, was included in Medicare
Baiji Shenzhou announced that bevacizumab injection is a biological analogue of pubeshi ® Commercial listing in China
Exclusive Interview with Liu Di, Managing Director of Peakview Capital
May 21, 2022 12:51 PM